ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

Therapy resistance is a major clinical problem in cancer medicine and crucial for disease relapse and progression. Therefore, the clinical need to overcome it, particularly for aggressive tumors such as pancreatic cancer, is very high. Aberrant activation of an epithelial–mesenchymal transition (EMT...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EMBO Mol Med
Hauptverfasser: Meidhof, Simone, Brabletz, Simone, Lehmann, Waltraut, Preca, Bogdan-Tiberius, Mock, Kerstin, Ruh, Manuel, Schüler, Julia, Berthold, Maria, Weber, Anika, Burk, Ulrike, Lübbert, Michael, Puhr, Martin, Culig, Zoran, Wellner, Ulrich, Keck, Tobias, Bronsert, Peter, Küsters, Simon, Hopt, Ulrich T, Stemmler, Marc P, Brabletz, Thomas
Format: Artigo
Sprache:Inglês
Veröffentlicht: BlackWell Publishing Ltd 2015
Schlagworte:
Research Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4459821/
https://ncbi.nlm.nih.gov/pubmed/25872941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201404396
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge